Health

BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal, Bolstering Leadership in Rare Diseases and Driving Growth

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin…

Read MoreBioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal, Bolstering Leadership in Rare Diseases and Driving Growth

BioNTech Completes Acquisition of CureVac N.V., Including Follow-on Offering, to Bolster Leadership in mRNA Innovation

BioNTech Completes Acquisition of CureVac N.V., Including Follow-on Offering Period, to Bolster Its Leading Position in the mRNA Space BioNTech SE today announced the closing of its acquisition of CureVac N.V…

Read MoreBioNTech Completes Acquisition of CureVac N.V., Including Follow-on Offering, to Bolster Leadership in mRNA Innovation